Endocyte Inc. Company Profile

23:23 EDT 20th October 2017 | BioPortfolio

News Articles [27 Associated News Articles listed on BioPortfolio]

Endocyte slumps on staff and R&D cuts

Shares hit an all-time low as Endocyte "refocuses" and slashes workforce.

Endocyte to cut workforce 40%

Endocyte, a provider developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, announced updates on clinical development for EC1456, its folate ...

Endocyte in-licenses Phase III-ready PSMA-targeted radioligand therapy

US biopharma firm Endocyte has executed an exclusive worldwide license of PSMA-617 from ABX GmbH.

Endocyte Adds Phase 3-Ready Prostate Cancer Drug with ABX Deal

Four months after two Endocyte drug candidates stumbled in early-stage studies, sparking a corporate shakeup, the company has signed a deal landing an experimental prostate cancer treatment that it sa...

Endocyte licenses radioligand prostate cancer therapy from ABX GMBH

Endocyte Inc. received exclusive global rights to the radioligand therapeutic PSMA617 (177LuPSMA617) from ABX GMBH.

STAT Plus: How a whole lot of hype sent Endocyte’s stock soaring for no good reason

Endocyte's stock price has quadrupled since it licensed an experimental prostate cancer drug. Problem is, the drug is not likely to work — or sell — well.

Endocyte announces exclusive worldwide license of PSMA-targeted radioligand therapy for development in prostate cancer

Endocyte has announced the completion of an exclusive worldwide license of PSMA-617 from ABX GmbH.

Endocyte bounces back with late-stage prostate cancer deal

Endocyte saw its share price take off yesterday after it acquired rights to a promising late-stage cancer therapy. The company’s stock rose more than 150% in a day, with investors sensing that the ...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Extension Study of EC145 for Subjects Enrolled in a Previous Study With EC145

This extension protocol is for those subjects that have completed the allowed duration of participation in an Endocyte-sponsored clinical trial of EC145 and have continuing evidence of cli...

Companies [4 Associated Companies listed on BioPortfolio]

Endocyte Incorporated

Endocyte, Inc is a biotechnology company focused on vitamin based drug targeting and delivery systems. Vitamins are essential components for specific biological cellular functions. Endocyte's mission ...

Endocyte, Inc.

Endocyte is a privately held biotechnology company with headquarters in the Purdue Research Park of West Lafayette, IN. Based on the applications of Endocyte’s advanced propr...


Endocyte is developing a new generation of receptor-targeted therapeutics or "smart drugs" for the treatment of cancer and autoimmune diseases. Current non-targeted drugs are usually toxic to normal h...

Merck and Endocyte

Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines,...

More Information about "Endocyte Inc." on BioPortfolio

We have published hundreds of Endocyte Inc. news stories on BioPortfolio along with dozens of Endocyte Inc. Clinical Trials and PubMed Articles about Endocyte Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Endocyte Inc. Companies in our database. You can also find out about relevant Endocyte Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record